Jacqualyn Fouse

Agios offloads oncology unit to Servier for $1.8B upfront

Agios' roots are in cancer drug development, but it’s passing that baton to Servier as it doubles down on its programs in genetically defined disease.

Amirah Al Idrus Dec 21, 2020 7:00am

Celgene president, COO Jackie Fouse to make shock departure

Feb 24, 2017 3:40am